10 Stocks Left Behind in a Roaring Market

2. ImmunityBio Inc. (NASDAQ:IBRX)

ImmunityBio finished the session down sharply on Wednesday, as investors resorted to profit-taking after touching a new record high during the day.

At intra-day trading, ImmunityBio Inc. (NASDAQ:IBRX) soared to its highest price of $12.43 before giving up all gains to finish the day down by 17.40 percent at $9.54 apiece.

The profit-taking followed the company’s strong financial and operating highlights last year, with total revenues expanding by 671 percent to $113 million from only $14.7 million in 2024.

Total revenues were supported by a 700 percent jump in net product revenues, thanks to a 750 percent sales volume expansion from its bladder cancer treatment, Anktiva.

However, ImmunityBio Inc. (NASDAQ:IBRX) remained at a net loss attributable to shareholders of $351.4 million, albeit narrower by 15 percent than the $413.56 million in 2024.

In the fourth quarter alone, revenues increased by 407 percent to $38.28 million from $7.5 million year-on-year, while attributable net loss increased by 4.6 percent to $61.9 million from $59.16 million year-on-year.

Optimism was further bolstered by a series of regulatory approvals earlier, paving the way for ImmunityBio Inc.’s (NASDAQ:IBRX) sales expansion of Anktiva in 33 international markets, including the United Kingdom, European Union members, and Saudi Arabia.

Three other clinical trials are planned over the next three years to test Anktiva’s efficacy in other therapeutic areas, including its use alongside standard-of-care treatments, CAR-NK / M-ceNK, and in treating lymphopenia.